Orforglipron
Also known as: LY3502970
Orforglipron is an oral GLP-1 receptor agonist developed by Eli Lilly that demonstrates significant weight loss and glycemic control effects in clinical trials. This non-peptide small molecule offers the benefits of traditional GLP-1 therapies without requiring injection.
Orforglipron is a 601.61 g/mol research peptide. Orforglipron is an oral GLP-1 receptor agonist developed by Eli Lilly that demonstrates significant weight loss and glycemic control effects in clinical trials. This non-peptide small molecule offers the benefits of traditional GLP-1 therapies without requiring injection.
Also called: LY3502970
601.61 g/mol
Molecular Weight
Daltons
3
Strong Evidence
benefits
3
Studies Cited
peer-reviewed
12-45
Typical Dose
mg
Overview
Orforglipron represents a breakthrough in metabolic medicine as the first oral, non-peptide GLP-1 receptor agonist to reach advanced clinical development. Unlike injectable GLP-1 peptides such as semaglutide or liraglutide, this compound maintains receptor activity while surviving the digestive system. The molecule activates GLP-1 receptors in the pancreas, brain, and gastrointestinal tract to regulate blood sugar, slow gastric emptying, and reduce appetite. Clinical studies show substantial weight reduction - often exceeding 10% of baseline body weight - along with improved insulin sensitivity and cardiovascular markers. Researchers study orforglipron for its potential to treat obesity, type 2 diabetes, and metabolic syndrome through a convenient oral dosing regimen.
Key Takeaways: Orforglipron
- Strongest evidence supports Orforglipron for substantial weight loss and improved glycemic control
- Research doses typically range from 12 to 45 mg via oral
- 3 benefits with strong evidence, 2 moderate, 1 preliminary
- Half-life: 24-30 hours
- 3 cited research studies in this guide
Mechanism of Action
Orforglipron binds to and activates GLP-1 receptors throughout the body, triggering multiple metabolic pathways. Pancreatic beta cells increase insulin secretion in response to glucose, while alpha cells reduce glucagon release. The compound crosses the blood-brain barrier to activate hypothalamic GLP-1 receptors, suppressing appetite and food intake. Gastric motility decreases through vagal nerve stimulation, extending satiety signals. Unlike peptide GLP-1 agonists, orforglipron's small molecule structure resists degradation by DPP-4 enzymes and survives gastric acid exposure.
Research Benefits
Orforglipron at a Glance
Orforglipron binds to and activates GLP-1 receptors throughout the body, triggering multiple metabolic pathways.
Substantial Weight Loss
Strong EvidenceClinical trials demonstrate 10-15% body weight reduction at therapeutic doses, comparable to injectable GLP-1 agonists. The compound reduces both visceral and subcutaneous fat through sustained appetite suppression and metabolic enhancement.
Improved Glycemic Control
Strong EvidenceOrforglipron lowers HbA1c by 1.5-2.0% in diabetic patients through enhanced insulin sensitivity and reduced hepatic glucose production. Postprandial glucose spikes decrease significantly within weeks of treatment initiation.
Enhanced Satiety and Appetite Control
Strong EvidencePatients report prolonged fullness and reduced food cravings within days of starting treatment. Brain imaging studies confirm activation of satiety centers and reduced reward responses to food stimuli.
Cardiovascular Risk Reduction
Moderate EvidenceStudies show improvements in blood pressure, triglycerides, and inflammatory markers. The compound may reduce cardiovascular events through weight loss and direct vascular effects, though long-term outcome data remains limited.
Improved Insulin Sensitivity
Moderate EvidenceOrforglipron enhances peripheral glucose uptake and reduces insulin resistance markers. The effect occurs independently of weight loss, suggesting direct metabolic benefits beyond caloric restriction.
Liver Fat Reduction
PreliminaryMRI studies demonstrate significant decreases in hepatic steatosis and liver enzyme levels. The compound may prevent progression to non-alcoholic steatohepatitis through improved lipid metabolism.
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Weight loss research | 12–45 mg | oral |
| Metabolic studies | 24–36 mg | oral |
| Diabetes research | 36–45 mg | oral |
Frequency
Once daily
Timing
Morning, with or without food
Cycle Length
12-52 weeks in clinical studies
Research Notes
- 1Dose escalation typically occurs every 4 weeks to minimize gastrointestinal side effects
- 2Take at consistent time daily for optimal plasma levels
- 3No food restrictions required, unlike some oral diabetes medications
- 4Research protocols often include 4-week washout periods between cycles
Reconstitution Guide
Standard Reconstitution
Vial Size
0 mg
Bacteriostatic Water
0 mL
Concentration
NaN mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
Orforglipron vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 0 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at Room temperature. 36 months.
Storage Temperature
Room temperature
Shelf Life
36 months
Important Notes
- •Supplied as oral tablets, no reconstitution required
- •Store in original container to protect from moisture
- •Stable at temperatures up to 30°C (86°F)
Orforglipron Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
Orforglipron Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Nausea (most common, usually transient)
- !Vomiting and gastrointestinal upset
- !Diarrhea or constipation
- !Decreased appetite and early satiety
- !Headache and dizziness
- !Fatigue and weakness
- !Abdominal pain or discomfort
- !Potential pancreatitis (rare but serious)
- !Gallbladder disorders including gallstones
- !Hypoglycemia when combined with insulin or sulfonylureas
Potential Interactions
- ⚡Insulin and insulin secretagogues (increased hypoglycemia risk)
- ⚡Warfarin and anticoagulants (potential INR changes)
- ⚡Oral medications with narrow absorption windows (delayed gastric emptying)
- ⚡Sulfonylureas (enhanced glucose-lowering effects)
- ⚡Digoxin (altered absorption due to gastric motility changes)
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Phase 2 Study of Orforglipron in Adults with Obesity
Randomized trial of 272 adults with obesity showed dose-dependent weight loss up to 14.7% with 45mg daily dose over 36 weeks, with acceptable safety profile.
Efficacy and Safety of Oral GLP-1 Receptor Agonist LY3502970
Phase 2b study in type 2 diabetes patients demonstrated HbA1c reduction of 1.6% and weight loss of 9.6% with 36mg daily dose over 26 weeks.
Pharmacokinetics and Pharmacodynamics of Orforglipron
First-in-human study established dose-response relationships and confirmed 24-hour half-life enabling once-daily dosing with sustained GLP-1 receptor activation.
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
Clinical trials suggest orforglipron produces similar weight loss to injectable semaglutide (10-15% body weight reduction) but with the convenience of oral administration. Head-to-head studies are ongoing to establish direct comparisons.
Orforglipron is a non-peptide small molecule that can be taken orally, unlike injectable peptide GLP-1 agonists. It resists digestive breakdown and maintains receptor activity without requiring injection, offering similar efficacy with improved convenience.
Yes, orforglipron can be taken with or without food. Clinical studies show no significant impact of meals on absorption or effectiveness, providing dosing flexibility compared to some other oral diabetes medications.
Most patients begin losing weight within the first 4-8 weeks of treatment, with maximum effects typically observed after 20-26 weeks. The rate of weight loss averages 1-2 pounds per week during the active phase.
Nausea is the most frequent side effect, affecting about 40% of patients initially but usually decreasing over time. Other common effects include vomiting, diarrhea, and decreased appetite. Most gastrointestinal side effects are mild to moderate and transient.
Current clinical trials extend up to 68 weeks, showing maintained efficacy and acceptable safety. Long-term studies are ongoing to establish safety beyond one year. Regular monitoring for pancreatitis and gallbladder issues is recommended.
Orforglipron alone rarely causes hypoglycemia because it works through glucose-dependent mechanisms. However, when combined with insulin or sulfonylureas, hypoglycemia risk increases and dose adjustments may be necessary.
Research protocols typically start at 12mg daily and escalate every 4 weeks to minimize side effects. The target therapeutic dose ranges from 24-45mg daily depending on the indication and individual response.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.